ITGA6 and vulva cancer: Notably, post-therapeutic PD-L1+ CD49f+ CD133+ numbers ≥ 5/ml in patients with vulvar cancer and ≥ 2/ml in patients with cervical cancer were associated with reduced recurrence-free survival on follow-up.